Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population
- DOI
- 10.1016/s1470-2045(26)00390-6
- Published
- 2026-09
- Container
- The Lancet Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-26-00390-6,
title = {Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population},
author = {Clare Turnbull and Sandra Perdomo and Susan Domchek and William D Foulkes and Paul Pharoah and Patricia Ashton-Prolla and Bhawna Sirohi and Joaquin Mateo and Hilary A Robbins and Richard Sullivan and Mark Lawler and Raffaella Casolino},
year = {2026},
journal = {The Lancet Oncology},
doi = {10.1016/s1470-2045(26)00390-6},
url = {https://doi.org/10.1016/s1470-2045(26)00390-6}
}RIS
TY - JOUR TI - Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population AU - Clare Turnbull AU - Sandra Perdomo AU - Susan Domchek AU - William D Foulkes AU - Paul Pharoah AU - Patricia Ashton-Prolla AU - Bhawna Sirohi AU - Joaquin Mateo AU - Hilary A Robbins AU - Richard Sullivan AU - Mark Lawler AU - Raffaella Casolino PY - 2026 JO - The Lancet Oncology DO - 10.1016/s1470-2045(26)00390-6 UR - https://doi.org/10.1016/s1470-2045(26)00390-6 ER -
APA
Turnbull, C., Perdomo, S., Domchek, S., Foulkes, W. D., Pharoah, P., Ashton-Prolla, P., Sirohi, B., Mateo, J., Robbins, H. A., Sullivan, R., Lawler, M., & Casolino, R. (2026). Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00390-6
Source records
- crossref · retrieved 2026-09-26T23:08:41.269Z